Información de la revista
Vol. 98. Núm. 8.
Páginas 526-530 (Octubre 2007)
Vol. 98. Núm. 8.
Páginas 526-530 (Octubre 2007)
Practical dermatology
Acceso a texto completo
Corticosteroids and Osteporosis
Corticoides y Osteoporosis
M. García-Bustínduya,
Autor para correspondencia

Correspondence: Servicio de Dermatología, Hospital Universitario de Canarias, Ofra, s/n, 38320 La Laguna, Tenerife, Spain.
, M.A. Gantesb
a Servicio de Dermatología, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
b Servicio de Reumatología, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Este artículo ha recibido
Información del artículo
Descargar PDF

Corticosteroids are the principal cause of secondary osteoporosis due to drug treatment. Doses of more than 5 mg daily and periods of treatment lasting more than 3 months increase the risk of osteoporosis and fragility fractures. It is therefore essential to be aware of measures to reduce the risk of osteoporosis in our patients.

Key words:

La primera causa de osteoporosis secundaria a fármacos son los glucocorticoides. Dosis diarias superiores a 5 mg o dosificación durante más de 3 meses incrementan la osteoporosis y las fracturas por fragilidad. Resulta crucial conocer las medidas para minimizar la osteoporosis en nuestros enfermos.

Palabras clave:
El Texto completo está disponible en PDF
M.B. Sulzberger, V.H. Witten.
Effect of topically applied compound F in selected dermatoses.
J Invest Dermatol, 19 (1952), pp. 101-102
B. Brazzini, N. Pimpinelli.
New and established topical corticosteroids in Dermatology. Clinical pharmacology and therapeutic use.
Am J Clin Dermatol, 3 (2002), pp. 47-58
A. Markham, H.M. Bryson.
Deflazacort. A review of its pharmacological properties and therapeutic efficacy.
Drugs, 50 (1995), pp. 317-333
C. Gennari.
Differential effect of glucocorticoids on calcium absorption and bone mass.
Br J Rheumatol, 32 (1993), pp. S11-S14
D.B. Robertson, H.I. Maibach.
Adverse systemic effects of TCS.
TCS, pp. 163-169
L.G. Raisz.
Pathogenesis of osteoporosis: concepts, conflicts and prospects.
J Clin Invest, 115 (2005), pp. 3318-3325
NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy.
Osteoporosis prevention, diagnosis, and therapy.
JAMA, 285 (2001), pp. 785-795
A.M. Parfitt, A.R. Villanueva, J. Foldes, D.S. Rao.
Relations between histologic indexes of bone formation: implications for the pathogenesis of spinal osteoporosis.
J Bone Miner Res, 10 (1995), pp. 466-473
EPOS Group.
Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS).
J Bone Miner Res, 17 (2002), pp. 716-724
M.R. MacAdams, R.H. White, B.E. Chipps.
Reduction of serum testosterone levels during chronic glucocorticoid therapy.
Ann Intern Med, 104 (1986), pp. 648-651
Y.S. Chyun, B.E. Kream, L.G. Raisz.
Cortisol decreases bone formation by inhibiting periosteal cell proliferation.
Endocrinology, 114 (1984), pp. 477-480
P.N. Sambrook, J.A. Eisman, G.D. Champion, N.A. Pocock.
Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.
Arthritis Rheum, 31 (1988), pp. 973-978
R.G. Klein, S.B. Arnaud, J.C. Gallagher, H.F. Deluca, B.L. Riggs.
Intestinal calcium absorption in exogenous hypercortisolism. Role of 25-hydroxyvitamin D and corticosteroid dose.
J Clin Invest, 60 (1977), pp. 253-259
B.P. Lukert, L.G. Raixz.
Glucocorticoid-induced osteoporosis: Pathogenesis and management.
Ann Intern Med, 112 (1990), pp. 352-364
R.F. Laan, P.L. van Riel, L.B. van de Putte, L.J. van Erning, M.A. van’t Hof, J.A. Lemmens.
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study.
Ann Intern Med, 119 (1993), pp. 963-968
C. Cooper, C. Coupland, M. Mitchell.
Rheumatoid arthritis, corticosteroid therapy and hip fracture.
Ann Rheum Dis, 54 (1995), pp. 49-52
G.M. Hall, T.D. Spector, P.D. Delmas.
Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy.
Arthritis Rheum, 38 (1995), pp. 902-906
N.A. Morrison, J.C. Qi, A. Tokita, P.J. Kelly, L. Crofts, T.V. Nguyen, et al.
Prediction of bone density from vitamin D receptor alleles.
Nature, 367 (1994), pp. 284-287
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update.
B.T. Summey, G. Yosipovitch.
Glucocorticoid-induced bone loss in dermatologic patients.
Arch Dermatol, 142 (2006), pp. 82-90
Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Actas Dermo-Sifiliográficas
Opciones de artículo
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?